Breakthrough melanoma treatment listed on PBS
The pre-surgery use of combination immunotherapy as frontline treatment for high risk melanoma is now listed on the Pharmaceutical Benefits Scheme (PBS) and subsidised for all Australian patients.
MIA clinicians & researchers share latest results at ASCO25
Read more about MIA clinicians and researchers in Chicago for ASCO25 - the American Society of Clinical Oncology Annual Meeting - to share latest research and clinical trial results with international colleagues.
Minimising surgery and drug intervention
Three studies led by researchers at Melanoma Institute Australia (MIA) are paving the way for less surgical and drug intervention for early stage melanoma patients.
MIA awarded prestigious NHMRC grant
The NHMRC grant will enable MIA to lead an international clinical trial aiming to safely reduce surgery for high risk Stage III melanoma patients who have had a good response to neoadjuvant immunotherapy.
World-first experimental cancer treatment paves way for clinical trial
Nature Medicine has published a peer-reviewed paper detailing the experimental glioblastoma cancer treatment developed by Professor Georgina Long AO, Medical Director of Melanoma Institute Australia, paving the way for a clinical trial to be conducted by researchers at The Brain Cancer Centre in Melbourne.
From just 16 weeks’ survival to long term disease control
Newly released long-term data from a groundbreaking clinical trial for advanced melanoma patients whose disease had spread to their brain has proven that long-term disease control has been achieved for over 50% of patients given combination immunotherapy as first line treatment.
$2.1 million to help boost cancer research in NSW
This World Cancer Research Day, the NSW Government is committing $2.1 million in research grant funding, with almost $700k awarded to MIA's Prof Long for an imaging system that will allow researchers to better visualise & understand tumour cell interactions.
MIA researchers sharing world stage at ESMO24
MIA’s leading experts and early career researchers have shared the world stage at the annual European Society for Medical Oncology (ESMO) Congress in Barcelona.
Preventing disease recurrence in BRAF positive melanoma patients
Final results of the COMBI-AD clinical trial, published in New England Journal of Medicine, show significant benefit in preventing disease progression in BRAF positive Stage III melanoma patients.
‘Tour of Honour’ for our Australians of the Year
Our 2024 Australians of the Year recently explored the Northern Territory, as part of a visit organised by the Australia Day Council. View the photo album.